Dexcom Achieves 13% Q2 Revenue Growth as FDA Approves OTC Glucose Biosensor Stelo for Pediatric Use

August 9, 2026

Medical Design and Outsourcing USA

Overview

Dexcom reported a robust 13% year-over-year revenue growth in Q2 2026, demonstrating the efficacy of its CGM technology in non-insulin-using Type 2 diabetes patients. Concurrently, the U.S. FDA granted approval for Dexcom’s over-the-counter (OTC) glucose biosensor, Stelo, for pediatric patients with prediabetes and diabetes—marking the first OTC CGM authorized for use in children. This approval is strategically significant for expanding Stelo’s market amidst rising prediabetes and Type 2 diabetes trends in children and adolescents.

In Depth

Key Findings

Dexcom achieved a robust 13% year-over-year revenue growth in the second quarter of 2026, demonstrating strong market performance for its continuous glucose monitoring (CGM) products. Simultaneously, the U.S. FDA granted approval for Dexcom’s over-the-counter (OTC) glucose biosensor, ‘Stelo,’ for pediatric patients with prediabetes and diabetes. This landmark approval marks the first time an OTC CGM device has been authorized for use in children, representing a crucial milestone in the company’s market expansion strategy.

Technical/Clinical Details

Dexcom’s Q2 financial results were primarily driven by strong sales of its flagship CGM products and increasing penetration of its technology among non-insulin-using Type 2 diabetes patients. This growth validates the clinical value its products offer across a broad spectrum of diabetes populations. The FDA’s pediatric approval for Stelo addresses the rising prevalence of prediabetes and Type 2 diabetes in children and adolescents. Clinical trials indicated that Stelo provides safe and accurate glucose monitoring in pediatric patients, proving beneficial for disease management. This approval empowers parents to monitor their children’s glucose status without a prescription, facilitating earlier intervention and improved disease management.

Background & Context

The global diabetes population continues to grow, with the increasing incidence of Type 2 diabetes in children and adolescents posing an urgent public health challenge. Traditional CGMs have required prescriptions and were primarily used by adult patients. Stelo’s OTC pediatric approval addresses this unmet need, opening a new market segment. From a market perspective, this approval allows Dexcom to acquire new customer demographics and establish leadership in the OTC market. Competitors are also developing similar OTC products, suggesting an intensifying market landscape ahead.

Strategic Significance & Outlook

The OTC pediatric approval for Stelo clearly demonstrates Dexcom’s strategic push beyond traditional diabetes management into broader healthcare markets, particularly preventive medicine and wellness. The company is expected to enhance educational programs and support systems for pediatric patients and their guardians, accelerating Stelo’s adoption. Furthermore, the combination of real-time glucose data with AI-driven insights is anticipated to accelerate the development of more personalized health management solutions, fundamentally transforming diabetes care and enabling more patients to benefit from early disease detection and effective management.

Source: https://www.mddionline.com/diabetes/analysts-love-dexcom-s-q2-results-but-competition-is-heating-up

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.